Cargando…

SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June–July 2020

BACKGROUND: Estimating the cumulative prevalence of SARS-COV-2 will help to understand the epidemic, contagion, and immunity to COVID-19 in vulnerable populations. The objective is to determine the extent of infection in the general population and the cumulative incidence by age group. METHODS: It w...

Descripción completa

Detalles Bibliográficos
Autores principales: Díaz-Vélez, Cristian, Failoc-Rojas, Virgilio E., Valladares-Garrido, Mario J., Colchado, Juan, Carrera-Acosta, Lourdes, Becerra, Mileny, Moreno Paico, Dafne, Ocampo-Salazar, Elgin Thom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034367/
https://www.ncbi.nlm.nih.gov/pubmed/33868828
http://dx.doi.org/10.7717/peerj.11210
_version_ 1783676533255176192
author Díaz-Vélez, Cristian
Failoc-Rojas, Virgilio E.
Valladares-Garrido, Mario J.
Colchado, Juan
Carrera-Acosta, Lourdes
Becerra, Mileny
Moreno Paico, Dafne
Ocampo-Salazar, Elgin Thom
author_facet Díaz-Vélez, Cristian
Failoc-Rojas, Virgilio E.
Valladares-Garrido, Mario J.
Colchado, Juan
Carrera-Acosta, Lourdes
Becerra, Mileny
Moreno Paico, Dafne
Ocampo-Salazar, Elgin Thom
author_sort Díaz-Vélez, Cristian
collection PubMed
description BACKGROUND: Estimating the cumulative prevalence of SARS-COV-2 will help to understand the epidemic, contagion, and immunity to COVID-19 in vulnerable populations. The objective is to determine the extent of infection in the general population and the cumulative incidence by age group. METHODS: It was carried out with a longitudinal analytical study, in the population of the Lambayeque region, located in the north of Peru. The selection was carried out in multistages (districts, area, household, and finally choosing the interviewee within the house). Seroprevalence was estimated as a positive result of the rapid test whether it was positive IgM or positive IgG. An adjustment was made for the sampling weights used. RESULTS: The seroprevalence found in the region was 29.5%. Young people between 21 and 50 years old presented the highest seroprevalence frequencies. A total of 25.4% were asymptomatic. The most frequent complaint was dysgeusia and dysosmia (85.3% and 83.6%). Dysosmia (PR = 1.69), chest pain (PR = 1.49), back pain (PR = 1.45), cough (PR = 1.44), fever (PR = 1.41), general malaise (PR = 1.27) were associated factors with the higher the frequency of seropositivity for SARS-CoV-2. Reporting of complete isolation at home decreased the frequency of positivity (PR = 0.80), however, reporting having ARI contact (PR = 1.60), having contact with a confirmed case (PR = 1.51), and going to market (PR = 1.26) increased the frequency of positivity for SARS-CoV-2. CONCLUSION: These results suggest that Lambayeque is the region with the highest seroprevalence in the world, well above Spain, the United States and similar to a study in India.
format Online
Article
Text
id pubmed-8034367
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-80343672021-04-16 SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June–July 2020 Díaz-Vélez, Cristian Failoc-Rojas, Virgilio E. Valladares-Garrido, Mario J. Colchado, Juan Carrera-Acosta, Lourdes Becerra, Mileny Moreno Paico, Dafne Ocampo-Salazar, Elgin Thom PeerJ Epidemiology BACKGROUND: Estimating the cumulative prevalence of SARS-COV-2 will help to understand the epidemic, contagion, and immunity to COVID-19 in vulnerable populations. The objective is to determine the extent of infection in the general population and the cumulative incidence by age group. METHODS: It was carried out with a longitudinal analytical study, in the population of the Lambayeque region, located in the north of Peru. The selection was carried out in multistages (districts, area, household, and finally choosing the interviewee within the house). Seroprevalence was estimated as a positive result of the rapid test whether it was positive IgM or positive IgG. An adjustment was made for the sampling weights used. RESULTS: The seroprevalence found in the region was 29.5%. Young people between 21 and 50 years old presented the highest seroprevalence frequencies. A total of 25.4% were asymptomatic. The most frequent complaint was dysgeusia and dysosmia (85.3% and 83.6%). Dysosmia (PR = 1.69), chest pain (PR = 1.49), back pain (PR = 1.45), cough (PR = 1.44), fever (PR = 1.41), general malaise (PR = 1.27) were associated factors with the higher the frequency of seropositivity for SARS-CoV-2. Reporting of complete isolation at home decreased the frequency of positivity (PR = 0.80), however, reporting having ARI contact (PR = 1.60), having contact with a confirmed case (PR = 1.51), and going to market (PR = 1.26) increased the frequency of positivity for SARS-CoV-2. CONCLUSION: These results suggest that Lambayeque is the region with the highest seroprevalence in the world, well above Spain, the United States and similar to a study in India. PeerJ Inc. 2021-04-06 /pmc/articles/PMC8034367/ /pubmed/33868828 http://dx.doi.org/10.7717/peerj.11210 Text en © 2021 Díaz-Vélez et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Epidemiology
Díaz-Vélez, Cristian
Failoc-Rojas, Virgilio E.
Valladares-Garrido, Mario J.
Colchado, Juan
Carrera-Acosta, Lourdes
Becerra, Mileny
Moreno Paico, Dafne
Ocampo-Salazar, Elgin Thom
SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June–July 2020
title SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June–July 2020
title_full SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June–July 2020
title_fullStr SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June–July 2020
title_full_unstemmed SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June–July 2020
title_short SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June–July 2020
title_sort sars-cov-2 seroprevalence study in lambayeque, peru. june–july 2020
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034367/
https://www.ncbi.nlm.nih.gov/pubmed/33868828
http://dx.doi.org/10.7717/peerj.11210
work_keys_str_mv AT diazvelezcristian sarscov2seroprevalencestudyinlambayequeperujunejuly2020
AT failocrojasvirgilioe sarscov2seroprevalencestudyinlambayequeperujunejuly2020
AT valladaresgarridomarioj sarscov2seroprevalencestudyinlambayequeperujunejuly2020
AT colchadojuan sarscov2seroprevalencestudyinlambayequeperujunejuly2020
AT carreraacostalourdes sarscov2seroprevalencestudyinlambayequeperujunejuly2020
AT becerramileny sarscov2seroprevalencestudyinlambayequeperujunejuly2020
AT morenopaicodafne sarscov2seroprevalencestudyinlambayequeperujunejuly2020
AT ocamposalazarelginthom sarscov2seroprevalencestudyinlambayequeperujunejuly2020